POTOMAC, MARYLAND – March 4, 2025 – IGC Pharma, Inc. (“IGC†or the “Companyâ€) (NYSE American: IGC) today announced an advancement in its Artificial Intelligence (“AIâ€) platform with the development
January 28, 2025 – The “Company” is proud to announce its selection as one of the top 15 finalists in the PREPARE Challenge – Phase 2: Model Arena (Acoustic Track),
October 01, 2024Â The “Company” is proud to announce that it won 2 awards in the PREPARE Challenge (Pioneering Research for Early Prediction of Alzheimer’s and Related Dementias EUREKA Challenge), with
Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies
April, 9, 2024 – The “Company” today announces the addition of Pablo Arbelaez, Ph.D., an expert in artificial intelligence (“AIâ€) and one of the world’s top researchers. Dr. Arbelaez will
In Alzheimer’s disease research, the integration of artificial intelligence (AI) enables researchers to uncover patterns and biomarkers faster, facilitating earlier diagnosis and personalized therapies. Embracing these new technologies not only enhances the understanding of AD but also propels the development of innovative treatments for this complex neurological condition.
